Analyst Ratings For Karyopharm Therapeutics (NASDAQ:KPTI)
Today, Cantor Fitzgerald reiterated its Buy rating on Karyopharm Therapeutics (NASDAQ:KPTI).
Some recent analyst ratings include
- 3/21/2018-Cantor Fitzgerald Reiterated Rating of Buy.
- 3/16/2018-JPMorgan Chase & Co. Reiterated Rating of Overweight .
- 3/2/2018-Royal Bank of Canada Reiterated Rating of Buy.
- 10/13/2017-Jefferies Group Reiterated Rating of Buy.
Recent Insider Trading Activity For Karyopharm Therapeutics (NASDAQ:KPTI)
Karyopharm Therapeutics (NASDAQ:KPTI) has insider ownership of 14.71% and institutional ownership of 62.60%.
- On 3/19/2018 Michael Kauffman, CEO, sold 10,000 with an average share price of $15.29 per share and the total transaction amounting to $152,900.00.
- On 3/12/2018 Mansoor Raza Mirza, Director, sold 2,500 with an average share price of $17.01 per share and the total transaction amounting to $42,525.00.
- On 3/7/2018 Sharon Shacham, Insider, sold 10,000 with an average share price of $16.15 per share and the total transaction amounting to $161,500.00.
- On 3/5/2018 Christopher Brett Primiano, EVP, sold 2,500 with an average share price of $16.03 per share and the total transaction amounting to $40,075.00.
- On 2/20/2018 Michael Kauffman, CEO, sold 10,000 with an average share price of $14.79 per share and the total transaction amounting to $147,900.00.
- On 2/16/2018 Christopher Brett Primiano, EVP, sold 2,500 with an average share price of $15.01 per share and the total transaction amounting to $37,525.00.
- On 2/7/2018 Christopher Brett Primiano, EVP, sold 1,500 with an average share price of $13.00 per share and the total transaction amounting to $19,500.00.
Recent Trading Activity for Karyopharm Therapeutics (NASDAQ:KPTI)
Shares of Karyopharm Therapeutics closed the previous trading session at with 0.0 shares trading hands.